NCT02746952已完成1 期
Phase I, Open Label, Dose-escalation Study Followed by a Safety Expansion Part to Evaluate the Safety, Expansion and Persistence of a Single Dose of UCART19 (Allogeneic Engineered T-cells Expressing Anti-CD19 Chimeric Antigen Receptor), Administered Intravenously in Patients With Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukaemia (B-ALL)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 25
- 试验地点
- 18
- 主要终点
- Dose escalation part: Dose Limiting Toxicities (DLTs) occurence. Dose expansion part: AE throughout the study.
研究概览
简要总结
The study is in two parts: a dose escalation then a safety dose expansion. The purpose of the dose escalation part is to evaluate the safety and tolerability of ascending doses of UCART19 (dose-escalation part) given as a single infusion in patients with relapsed / refractory (R/R) B-cell acute lymphoblastic leukaemia (B-ALL), to determine the maximum tolerated dose (MTD), the recommended dose and the lymphodepletion regimen. The purpose of the safety dose expansion is to assess the safety and tolerability of the RD for UCART19.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 16 Years 至 69 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female participant
- •Age ≥ 16 years
- •Patient with relapsed or refractory CD19 positive B-acute lymphoblastic leukaemia (B-ALL) who have exhausted alternative treatment options
- •Estimated life expectancy ≥ 12 weeks (according to investigator's judgement)
- •Eastern Cooperative Oncology Group (ECOG) performance status < 2
排除标准
- •Previous treatment with gene or gene-modified cell therapy medicine products or adoptive T cell therapy
- •Use of previous anti-leukemic therapy (including approved therapies and other investigational products) within 5 half-lives prior to UCART19 administration
- •CD19 negative B-cell leukaemia
- •Burkitt cell or mixed lineage acute leukaemia
结局指标
主要结局
Dose escalation part: Dose Limiting Toxicities (DLTs) occurence. Dose expansion part: AE throughout the study.
时间窗: Dose Escalation: Up to day 28 post first UCART19 infusion. Dose Expansion: From inclusion to Month 12
次要结局
- Incidence and Severity of Adverse Events as a Measure of Safety and Tolerability(From inclusion to Month 12)
- Duration of remission(From the time that response criteria are first met until the date of progression or death (whatever the reason of death), whichever occurs first, assessed up to Month 12)
- Overall Survival (OS)(From the date of UCART19 administration to the date of death from any cause, assessed up to Month 12)
- Objective Remission Rate(At Day 28, Day 84, Month 4, Month 6, Month 9 and Month12)
- Progression Free Survival (PFS)(From the date of UCART19 administration until the date of progression or the date of death (whatever the reason of death), whichever occur first, assessed up to Month 12)
- Time to remission(From the date of UCART19 administration until the date that response criteria are met, assessed up to Month 12)
研究者
研究点 (18)
Loading locations...
相似试验
已完成
1 期
A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001)NeoplasmsNCT03918278Merck Sharp & Dohme LLC222
招募中
1 期
To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid TumorsAdvanced or Metastatic Solid TumorsNCT06752681Day One Biopharmaceuticals, Inc.300
已完成
1 期
Evaluation of the Safety and Efficacy of ASCA101 in Patients With Advanced Solid TumorsSolid TumorNCT05547906MetaFines18
招募中
1 期
A Phase 1 Study of LNCB74 in Advanced Solid TumorsOvarian CancerEndometrial CancerBiliary Tract CancerAdvanced or Metastatic Solid TumorsNon-Small Cell Lung CancerBreast CancerNCT06774963NextCure, Inc.145
已完成
1 期
NUC-3373 in Advanced Solid TumoursCancerNCT02723240University of Oxford62